{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T07:30:14Z","timestamp":1795246214953,"version":"4.10.3"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jneuroim.2025.578717","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T22:26:06Z","timestamp":1754778366000},"page":"578717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Neurotoxicity associated with chimeric antigen receptor T-cell therapy"],"prefix":"10.1016","volume":"407","author":[{"given":"Miriam","family":"Wronski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Seery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafqat","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Min","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578717_bb0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0015","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005459","article-title":"Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy","volume":"10","author":"Amidi","year":"2022","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41409-020-01029-4","article-title":"Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0030","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jtct.2023.12.261","article-title":"Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities \u2013 a Multicenter Retrospective Analysis","volume":"30","author":"Bajwa","year":"2024","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0040","series-title":"Excitatory Amino Acid Transmission in Health and Disease","article-title":"269Glutamate and Glutamate Receptors in Neurological Diseases","author":"Bal\u00e1zs","year":"2005"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0045","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2021-150838","article-title":"Change in Patients\u2019 Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360","volume":"138","author":"Barata","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0055","first-page":"10","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","author":"Belin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0060","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy","volume":"108","author":"Berger","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/neuonc\/noab174","article-title":"EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations","volume":"24","author":"Beuchat","year":"2022","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0075","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment","volume":"145","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0085","first-page":"501","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0090","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell\u2013Associated Neurotoxicity Syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1079181","article-title":"Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0105","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0110","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/iub.1078","article-title":"TAK1, more than just innate immunity","volume":"64","author":"Dai","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0135","series-title":"Journal for ImmunoTherapy of Cancer. BMC Campus, 4 Crinan ST, London N1 9XW, England","article-title":"Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study)","author":"DeAngelo","year":"2017"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0140","article-title":"DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities","volume":"12","author":"Deng","year":"2021","journal-title":"Cell Death &amp; Disease"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0145","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood.2024025679","article-title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","volume":"144","author":"Desch\u00eanes-Simard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0150","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.2024023933","article-title":"Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents","volume":"144","author":"Diorio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0155","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0160","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/acn3.51866","article-title":"Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative <scp>EEG<\/scp>","volume":"10","author":"Eckhardt","year":"2023","journal-title":"Ann. Clin. Translat. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001756-199701200-00011","article-title":"Activated human microglia produce the excitotoxin quinolinic acid","volume":"8","author":"Espey","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0170","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19508","article-title":"Incidence and clinical predictors of cranial nerve palsies (CNPs) post ciltacabtagene-autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"43","author":"Feliciano Salva","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0180","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","article-title":"The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies","volume":"103","author":"Fiedler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-\u03b1 and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0190","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0195","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s10072-023-06841-6","article-title":"Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series","volume":"44","author":"Fontanelli","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0200","series-title":"Anakinra [package insert]","author":"Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0205","series-title":"Food and Drug Administration Approved Cellular and Gene Therapy Products","year":"2025"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0215","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0220","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2023-180205","article-title":"Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort","volume":"142","author":"Frigault","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0225","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The Blood\u2013brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0230","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0235","series-title":"American Society of Hematology Washington, DC","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","author":"Garfall","year":"2016"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0240","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1182\/blood-2023-179506","article-title":"Easix Indices Predict CRS and Overall Survival in Adult CAR-T Cell Recipients","volume":"142","author":"Gavriilaki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0245","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0250","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0255","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0260","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0265","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0270","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0275","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0280","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0285","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0290","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00401-016-1551-3","article-title":"Angiopoietin-2-induced blood\u2013brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling","volume":"131","author":"Gurnik","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0295","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0300","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell\u2013associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0315","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNP.0000000000000669","article-title":"EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity","volume":"38","author":"Gust","year":"2021","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0325","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0330","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0335","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematol","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0350","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/biom12070998","article-title":"The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases","volume":"12","author":"Hestad","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0355","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell\u2013associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0360","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000026433","article-title":"Cytokine Effects on Glutamate Uptake by Human Astrocytes","volume":"7","author":"Hu","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0365","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200111","article-title":"Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion","volume":"10","author":"Huby","year":"2023","journal-title":"Neurol. Neuroimmunol. & Neuroinflammat."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005898","article-title":"CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity","volume":"11","author":"Jess","year":"2023","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0380","first-page":"12","article-title":"EEG-based grading of immune effector cell-associated neurotoxicity syndrome","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0385","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2021004889","article-title":"Fatal late-onset CAR T-cell\u2013mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma","volume":"5","author":"Jung","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0390","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0395","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103126","article-title":"Cognition following chimeric antigen receptor T-cell therapy: A systematic review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0405","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1111\/febs.13412","article-title":"The dynamic blood\u2013brain barrier","volume":"282","author":"Keaney","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0410","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy\u2014A Cohort Study","volume":"13","author":"Korell","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0420","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0425","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1182\/blood-2024-202851","article-title":"Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","volume":"144","author":"Kuznetsova","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0430","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0440","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0445","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0450","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","article-title":"Function and therapeutic value of astrocytes in neurological diseases","volume":"21","author":"Lee","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0455","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","article-title":"Reactive Astrocytes: Production, Function, and Therapeutic Potential","volume":"46","author":"Liddelow","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0460","doi-asserted-by":"crossref","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0465","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0475","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0480","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2025.01.884","article-title":"Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy","volume":"31","author":"Maillie","year":"2025","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0485","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/archneur.58.3.365","article-title":"Glutamate Transporters in Neurologic Disease","volume":"58","author":"Maragakis","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0490","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0495","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0500","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0505","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0510","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","article-title":"Impact of diagnostic investigations in the management of CAR T-cell\u2013associated neurotoxicity","volume":"8","author":"Mauget","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0525","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jnc.14574","article-title":"The S100B story: from biomarker to active factor in neural injury","volume":"148","author":"Michetti","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0535","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0540","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0545","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2023-188830","article-title":"CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0550","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0560","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2025.03.010","article-title":"Persistent Cognitive Dysfunction After Chimeric Antigen Receptor T-Cell Therapy in Adolescents and Young Adults","volume":"167","author":"Nagai","year":"2025","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0565","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","article-title":"Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy","volume":"106","author":"Nair","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0570","series-title":"Afferent pathways for autonomic and shivering thermoeffectors","first-page":"263","author":"Nakamura","year":"2018"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0575","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0580","series-title":"Common terminology criteria for adverse events (CTCAE). version 4.03","author":"National Cancer Institute","year":"2010"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0585","series-title":"Common terminology criteria for adverse events (CTCAE). version 5.0. In","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0590","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2022007381","article-title":"Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"6","author":"Nawas","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0595","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0600","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0605","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0610","doi-asserted-by":"crossref","unstructured":"Network NCC (2022) NCCN Guidelines\u00ae Updates: Management of Immunotherapy-Related Toxicities. J. Natl. Compr. Cancer Netw. 20:xiii-xv.","DOI":"10.6004\/jnccn.2022.204glup"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0615","series-title":"Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma","author":"Nie","year":"2024"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0620","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0625","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0630","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/01.LAB.0000082383.40635.FE","article-title":"Altered expression of angiopoietins during blood-brain barrier breakdown and angiogenesis","volume":"83","author":"Nourhaghighi","year":"2003","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0635","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0640","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00259-021-05562-2","article-title":"2-[18F]FDG-PET\/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS","volume":"49","author":"Paccagnella","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0645","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"issue":"126\u2013142","key":"10.1016\/j.jneuroim.2025.578717_bb0650","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0655","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1182\/blood-2022-169809","article-title":"Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0660","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ard.2025.03.018","article-title":"Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation","volume":"84","author":"Pecher","year":"2025","journal-title":"Ann. Rheum."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.11.016","article-title":"Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation","volume":"30","author":"Pedraza","year":"2024","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007635","article-title":"Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study","volume":"12","author":"Penack","year":"2024","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0675","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0680","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0685","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00415-021-10766-5","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","volume":"269","author":"Pensato","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0690","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00415-023-11595-4","article-title":"CAR t-cell therapy in BOlogNa\u2013NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON\u2013NEUTRAL): proposed protocol and results from an Italian study","volume":"270","author":"Pensato","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0695","first-page":"4348","article-title":"CAR T cell Toxicities: Bedside to Bench - How Novel Toxicities Inform Laboratory Investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0700","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/ijms25010644","article-title":"The Mechanisms of Altered Blood\u2013Brain Barrier Permeability in CD19 CAR T\u2013Cell Recipients","volume":"25","author":"Pinto","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0705","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/jon.13138","article-title":"Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: A review","volume":"33","author":"Pinto","year":"2023","journal-title":"J. Neuroimaging"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0710","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0715","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell\u2013based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0720","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduction and Targeted","volume":"8","author":"Qin","year":"2023","journal-title":"Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.54457\/DR.202101005","article-title":"Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report","volume":"1","author":"Qiu","year":"2021","journal-title":"Diseases & Research"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0730","series-title":"Endothelial Signaling in Development and Disease","first-page":"313","article-title":"The Angiopoietin\u2014Tie System: Common Signaling Pathways for Angiogenesis, Cancer, and Inflammation","author":"Reiss","year":"2015"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0735","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS\/Combined Relapsed\/Refractory ALL","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0740","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2024-205103","article-title":"CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0745","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed\/Refractory Aggressive B Cell Lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0750","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0755","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0760","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0765","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0770","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16174","article-title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study","volume":"31","author":"Sales","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0775","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0780","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0785","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0790","first-page":"2443","article-title":"How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0795","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/ni1255","article-title":"Essential function for the kinase TAK1 in innate and adaptive immune responses","volume":"6","author":"Sato","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0800","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/19418744221128852","article-title":"Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy","volume":"13","author":"Satyanarayan","year":"2023","journal-title":"The Neurohospitalist"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0805","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00657-x","article-title":"Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)","volume":"12","author":"Saw","year":"2022","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0810","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0815","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0820","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0825","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2352-3026(22)00258-7","article-title":"CD19 CAR T cells for infants and young children","volume":"9","author":"Shalabi","year":"2022","journal-title":"The Lancet Haematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0830","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0835","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0840","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836452","article-title":"Immunotherapy Associated Neurotoxicity in Pediatric Oncology","volume":"12","author":"Shalabi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0845","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jha2.286","article-title":"Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma","volume":"3","author":"Sheikh","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0850","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1017\/S1478951514000947","article-title":"Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium","volume":"13","author":"Silver","year":"2015","journal-title":"Palliative and Supportive Care"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0855","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1148\/radiol.2021210760","article-title":"Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy","volume":"302","author":"Smith","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0860","article-title":"CAR-T cell therapy: current limitations and potential strategies. Blood","volume":"11","author":"Sterner","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0865","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ijc.34635","article-title":"Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control","volume":"153","author":"Stock","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0870","doi-asserted-by":"crossref","first-page":"1002004","DOI":"10.3389\/fnins.2022.1002004","article-title":"An integrated cytokine and kynurenine network as the basis of neuroimmune communication","volume":"16","author":"Stone","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0875","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0880","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0885","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0890","doi-asserted-by":"crossref","first-page":"21362","DOI":"10.1074\/jbc.M600504200","article-title":"Tumor necrosis factor-\u03b1 induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner","volume":"281","author":"Takeuchi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0895","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/j.bbmt.2019.12.397","article-title":"Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience","volume":"26","author":"Tambaro","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0900","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0905","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell\u2013mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0910","article-title":"Programmable synthetic receptors: the next-generation of cell and gene therapies. Signal Transduction and Targeted","volume":"9","author":"Teng","year":"2024","journal-title":"Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0915","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2017-169","article-title":"JCAR015 in ALL: A Root-Cause Investigation","volume":"8","author":"Therapeutics","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0920","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0925","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema","volume":"77","author":"Torre","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0930","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","article-title":"Cornell Assessment of Pediatric Delirium","volume":"42","author":"Traube","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0935","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8 <sup>+<\/sup> and CD4 <sup>+<\/sup> CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0940","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0945","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0950","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.jtct.2023.12.532","article-title":"Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)","volume":"30","author":"Van De Donk","year":"2024","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0955","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0965","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbi.2005.10.005","article-title":"Release of cytokines by brain endothelial cells: a polarized response to lipopolysaccharide","volume":"20","author":"Verma","year":"2006","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0970","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neurol.2021.01.019","article-title":"Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report","volume":"178","author":"Vernier","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0975","first-page":"1","article-title":"Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome","author":"Vinnakota","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0980","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.jtct.2023.12.497","article-title":"Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase I Clinical Trial","volume":"30","author":"Voorhees","year":"2024","journal-title":"Transplantat. Cell. Therapy"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0985","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578717_bb0990","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death &amp; Disease"},{"key":"10.1016\/j.jneuroim.2025.578717_bb0995","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb1000","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large <scp>B<\/scp> cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb1005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gpb.2019.03.002","article-title":"Single-cell analysis of CAR-T cell activation reveals a mixed Th 1\/Th 2 response independent of differentiation","volume":"17","author":"Xhangolli","year":"2019","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.jneuroim.2025.578717_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0293-7","article-title":"Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response","volume":"5","author":"Xue","year":"2017","journal-title":"J. immunotherapy Cancer"},{"key":"10.1016\/j.jneuroim.2025.578717_bb1015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.12263","article-title":"IL-1\u03b2 and TNF-\u03b1 induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase","volume":"125","author":"Ye","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2025.578717_bb1020","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb1025","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jneuroim.2025.578717_bb1030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:51:49Z","timestamp":1779616309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":206,"alternative-id":["S0165572825001985"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578717","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotoxicity associated with chimeric antigen receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578717"}}